curasan AG
Annual General Meeting of curasan AG advocates strategy of the company
DGAP-News: curasan AG / Key word(s): AGM/EGM Annual General Meeting of curasan AG advocates strategy of the company Aschaffenburg, 29 June 2017 – curasan AG (ISIN DE0005494538), a leading specialist for medical products in the field of orthobiologics, presented today details of its business development in 2016 and 2017 within the framework of its Annual General Meeting. Among other things, the voting shareholders also decided on the new composition of the Supervisory Board in the context of the regular elections. In his presentation, CEO Michael Schlenk first explained in detail the current strategy of the company and pointed out to the attending shareholders (40,97 percent of the share capital of the company by the time of the voting) the importance of today’s extensive investment of the company in sales and marketing for the future viability of curasan AG. “We mainly receive positive feedback from our investors,” Schlenk says. “This confirms our course and shows us that we can convince the market.” Among the items on the agenda, this year, in particular item 4, the new election of the Supervisory Board, emerged. As on the other agenda items, the voting shareholders also followed the management’s proposal on this point, and once again elected Dr. Detlef Wilke and as new members Dr. Tomas Kahn and Prof. Dr. Dirk Honold into the Supervisory Board. “I am very pleased that with Dr. Kahn and Prof. Dr. Honold we won two designated experts from the field of medical technology and finance with excellent networks for our company”, emphasizes Schlenk. “I expect many new impulses for our company from the new composition of the Supervisory Board.” Specifically, Items 2 to 6 were endorsed with the following percentage share of voting shares: Agenda item 2: 99.99 % Further details on the agenda items voted on and the presentation of today’s Annual General Meeting are available on the website of curasan AG at http://www.curasan.de/investors/hauptversammlung/. Contact curasan AG: Andrea Weidner About curasan AG:
29.06.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | curasan AG |
Lindigstraße 4 | |
63801 Kleinostheim | |
Germany | |
Phone: | 06027/40 900 0 |
Fax: | 06027/40 900 29 |
E-mail: | info@curasan.de |
Internet: | www.curasan.de |
ISIN: | DE0005494538 |
WKN: | 549453 |
Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |